Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 47, 2017 - Issue 9
1,099
Views
12
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

Long circulation nanostructured lipid carriers for gambogenic acid: formulation design, characterization, and pharmacokinetic

, , , , , , , , & show all
Pages 793-799 | Received 28 Jun 2016, Accepted 23 Aug 2016, Published online: 05 Dec 2016

References

  • Abe K, Higashi K. (2015). Effects of the PEG molecular weight of a PEG-lipid and cholesterol on PEG chain flexibility on liposomes surfaces. Colloids Surf A: Physicochem Eng Asp 17:1–9
  • Bajaj G, Kim MR, Mohammed SI, et al. (2012). Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. J Control Release 158:386–92
  • Chen HB, Zhou LZ, Mei L, et al. (2012). Gambogenic acid-induced time-and dose-dependent growth inhibition and apoptosis involving Akt pathway inactivation in U251 glioblastoma cells. J Nat Med 66:62–9
  • Cheng H, Su JJ, Peng JY, et al. (2011). Gambogenic acid inhibits proliferation of A549 cells through apoptosis inducing through up-regulation of the p38 MAPK cascade. J Asian Nat Prod Res 11:993–1002
  • Fu W, Zhang JF, Wang H, et al. (2012). Apoptosis induced by 1,3,6,7-tetrahydroxyxanthone in hepatocellular carcinoma and proteomic analysis. Apoptosis 17:842–51
  • Huang X, Chen YJ, Peng DY, et al. (2013). Solid lipid nanoparticles as delivery systems for Gambogenic acid. Colloids Surf B: Biointerfaces 102:391–7
  • Jia LJ, Shen JY, Zhang D, et al. (2012). In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers. Int J Biol Macromol 50:523–9
  • Jokerst JV, Lobovkina T, Gambhir SS. (2011). Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 6:715–28
  • Kim B, Han G, Toley BJ, et al. (2010). Tuning payload delivery in tumour cylindroids using gold nanoparticles. Nat Nanotechnol 5:465–72
  • Kim JH, Kim Y, Bae KH, et al. (2015). Tumor-targeted delivery of paclitaxel using low density lipoprotein-mimetic solid lipid. Nanopart Mol Pharm 11:33–9
  • Kumar MR, Aithal BK, Udupa N, et al. (2011). Formulation of plumbagin loaded long circulating pegylated liposomes: in vivo evaluation in C57BL/6J mice bearing B16F1 melanoma. Drug Deliv 18:511–22
  • Lee SB. Fractionated products obtained from Gamboge resin, and medical uses of the same, Patent, United States, US201110305784A1
  • Li QL, Cheng H, Zhu G, et al. (2010). Gambogenic acid inhibits proliferation of A549 cells through apoptosis-inducing and cell cycle arresting. Biol Pharm Bull 33:415–20
  • Lin TY, Fang Q, Peng DY, et al. (2013). PEGylated nonionic surfactant vesicles as drug delivery systems for Gambogenic acid. Drug Deliv 20:277–84
  • Liu X, Zhang Z, Jiang Y, et al. (2015). Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: characterization and evaluation. Drug Deliv 22:223–9
  • Lu H, Li B, Kang Y, et al. (2007). Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting. Cancer Chemother Pharmacol 59:175–81
  • Luan JJ, Zhang DR, Hao L, et al. (2014). Preparation, characterization and pharmacokinetics of Amoitone B-loaded long circulating nanostructured lipid carries. Colloids Surf B: Biointerfaces 114:255–60
  • Luo Q, Lin TY, Zhu T, et al. (2015). A novel glyceryl monoolein-bearing cubosomes for Gambogenic acid: preparation, cytotoxicity and intracellular uptake. Int J Pharm 493:30–9
  • Magdalena H-B, Bednarowicz M, Dobosz B, et al. (2015). Doxorubicin loaded PEG-b-poly(4-vinylbenzylphosphonate)coated magnetic iron oxide nanoparticles for targeted drug delivery. J Magn Magn Mater 384:320–7
  • Neupane YR, Srivastava M, Ahmad N, et al. (2014). Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment. Int J Pharm 477:601–12
  • Su W, Wang H, Wang S, et al. (2012). PEG/RGD-modified magnetic polymeric liposomes for controlled drug release and tumor cell targeting. Int J Pharm 426:170–81
  • Venosa GD, Hermida L, Batlle A, et al. (2008). Characterisation of liposomes containing aminolevulinic acid and derived esters. J Photochem Photobiol B: Biol 92:1–9
  • Wang DL, Zhan R, Tao XH, et al. (2012). Determination of Gambogenic acid and its pharmacokinetics in rat plasma by HPLC. Chin Pharmacol Bull 28:1164–7
  • Wang L, Luo Q, Lin TY, et al. (2014). PEGylated nanostructured lipid carriers(PEG-NLC) as a novel drug delivery system for Biochanin A. Drugs Dev Ind Pharm 6:1–9
  • Wang Q, Cheng HL, Zhou K, et al. (2014). Nanostructured lipid carriers as a delivery system of biochanin A. Drug Deliv 20:331–7
  • Yan F, Wang M, Chen H, et al. (2011). Gambogenic acid mediated apoptosis through the mitochondrial oxidative stress and inactivation of Akt signaling pathway in human nasopharyngeal carcinoma CNE-1 cells. Eur J Pharmacol 652:23–32
  • Yu XJ, Han QB, Wen ZS, et al. (2012). Gambogenic acid induces G1 arrest via GSK3β-dependent cyclin D1 degradation and triggers autophagy in lung cancer cells. Cancer Lett 322:185–94